Trevi Therapeutics (TRVI) Other Accumulated Expenses (2018 - 2026)
Trevi Therapeutics' quarterly Other Accumulated Expenses came in at $124000.0 in Q1 2026, up 44.19% year-on-year from $86000.0 in Q1 2025, and down 32.61% quarter-over-quarter from $184000.0 in Q4 2025.
Trevi Therapeutics has reported Other Accumulated Expenses for 9 years, with the latest figure at $124000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses rose 44.19% year-over-year to $124000.0; the trailing twelve-month figure through Mar 2026 stood at $124000.0 (up 44.19% YoY), and the FY2025 full-year result was $184000.0, up 327.91% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $124000.0, down from $184000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $498000.0 in Q4 2022, with the low at $6000.0 in Q4 2023.
- Average Other Accumulated Expenses over 5 years is $154882.4, with a median of $77000.0 recorded in 2022.
- Year-over-year, Other Accumulated Expenses slumped 98.8% in 2023 and soared 616.67% in 2024.
- Tracing TRVI's Other Accumulated Expenses over 5 years: stood at $498000.0 in 2022, then tumbled by 98.8% to $6000.0 in 2023, then soared by 616.67% to $43000.0 in 2024, then soared by 327.91% to $184000.0 in 2025, then plunged by 32.61% to $124000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $124000.0 (Q1 2026), $184000.0 (Q4 2025), and $126000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124,000.00 |
| Dec 31, 2025 | 184,000.00 |
| Sep 30, 2025 | 126,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 86,000.00 |
| Dec 31, 2024 | 43,000.00 |
| Sep 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | 53,000.00 |
| Mar 31, 2023 | 467,000.00 |
| Dec 31, 2022 | 498,000.00 |
| Sep 30, 2022 | 415,000.00 |
| Jun 30, 2022 | 332,000.00 |
| Mar 31, 2022 | 77,000.00 |
| Dec 31, 2021 | 79,000.00 |
| Sep 30, 2021 | 70,000.00 |
| Jun 30, 2021 | 149,000.00 |
| Mar 31, 2021 | 108,000.00 |
| Dec 31, 2020 | 158,000.00 |
| Sep 30, 2020 | 131,000.00 |
| Jun 30, 2020 | 181,000.00 |
| Mar 31, 2020 | 222,000.00 |
| Dec 31, 2019 | 303,000.00 |
| Sep 30, 2019 | 240,000.00 |
| Jun 30, 2019 | 144,000.00 |
| Dec 31, 2018 | 70,000.00 |